A Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors
Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Mar 10, 2023
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether a medication called oral minoxidil can help improve hair loss in children, teens, and young adults who have survived cancer. The researchers want to see if this medication is safe and if it has any side effects. They will also check how well participants can stick to their dosing schedule and how taking minoxidil affects their overall quality of life.
To be eligible for this study, participants should be between 6 and 18 years old and must have been diagnosed with cancer before the age of 17. They should have completed their cancer treatments, such as chemotherapy or radiation, at least one year before joining the study. Additionally, they need to have ongoing hair loss related to their previous cancer treatments for more than six months. Participants will receive the oral minoxidil and will be monitored for its effects and any side effects during the trial. This is a great opportunity for young cancer survivors experiencing hair loss to explore a potential treatment option.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients must have been diagnosed with cancer before the age of 17.
- • They must have completed either systemic or radiation therapy (cytotoxic chemotherapy and external beam radiation therapy) for their cancer at least 1 year prior to study entry.
- • They must be between 6-18 years old at the time of enrollment.
- • They must have a clinical diagnosis of persistent or late alopecia for \>6 months and that is definitely, probably, or possibly related to prior chemotherapy and/or radiation.
- Exclusion Criteria:
- • Had a history of alopecia prior to systemic or radiation therapy for cancer, or has alopecia unrelated to cancer treatment.
- • Have scalp disorders that preclude the evaluation of alopecia, such as psoriasis
- • Has a known hypersensitivity to minoxidil
- • Concurrent use of other therapies for alopecia
- • Concurrent active anticancer therapies (cytotoxic, targeted, endocrine, immunologic)
- • History of chronic sclerotic cutaneous GvHD affecting the scalp
- • Active chronic cutaneous GvHD
- • History of orthostatic or symptomatic hypotension, syncope related to hypotension; systolic less than or equal than 100 (for adults) and 90 (for children) at screening.
- • Pregnancy.
- • Cardiovascular disease that in the opinion of the cardiologist makes the patient unsuitable for therapy
- • Blood pressure less than the 5th percentile or less than 90/50 mmHg for children 10 years or older
About Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSKCC) is a world-renowned institution dedicated to cancer treatment, research, and education. As a leading clinical trial sponsor, MSKCC focuses on advancing innovative cancer therapies through rigorous scientific investigation and collaboration. The center's multidisciplinary team of experts employs cutting-edge methodologies to design and conduct trials that aim to improve patient outcomes and enhance understanding of cancer biology. With a commitment to translating research findings into clinical practice, MSKCC plays a pivotal role in shaping the future of oncology care and ensuring that patients have access to the latest therapeutic advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Alina Markova, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials